Innova Captab Ltd

Innova Captab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Innova Captab Ltd

₹ 848 -2.75%
22 May - close price
innovacaptab.com BSE: 544067 NSE: INNOVACAP
About

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

Key Points

Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain

Website BSE NSE
  • Market Cap ₹ 4,854 Cr.
  • Current Price ₹ 848
  • High / Low ₹ 1,021 / 608
  • Stock P/E 34.4
  • Book Value ₹ 191
  • Dividend Yield 0.24 %
  • ROCE 15.0 %
  • ROE 13.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has delivered good profit growth of 32.6% CAGR over last 5 years

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
241 233 283 302 263 294 318 316 315 352 380 450 448
214 202 242 258 225 252 268 270 267 299 329 381 383
Operating Profit 27 31 40 45 38 42 50 47 48 52 52 69 65
OPM % 11% 13% 14% 15% 14% 14% 16% 15% 15% 15% 14% 15% 15%
3 1 3 2 6 2 2 4 3 4 4 2 2
Interest 5 5 9 7 1 0 0 0 2 3 6 4 5
Depreciation 3 3 5 5 3 5 5 5 10 11 11 11 11
Profit before tax 21 25 30 35 40 39 47 46 39 43 39 56 51
Tax % 19% 28% 24% 29% 27% 25% 25% 25% 25% 27% 24% 24% 25%
17 18 23 25 29 29 35 34 30 31 30 42 38
EPS in Rs 3.59 3.66 4.77 4.39 5.02 5.15 6.12 5.98 5.17 5.42 5.18 7.37 6.65
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
356 373 411 801 926 1,081 1,244 1,630
315 322 356 704 813 927 1,057 1,387
Operating Profit 41 51 54 96 114 154 186 243
OPM % 11% 14% 13% 12% 12% 14% 15% 15%
0 1 1 3 9 12 12 7
Interest 6 5 4 6 20 21 2 17
Depreciation 11 10 6 8 11 16 25 45
Profit before tax 25 38 46 86 92 130 171 188
Tax % 20% 26% 26% 25% 26% 27% 25% 25%
20 28 34 64 68 94 128 141
EPS in Rs 165.67 232.42 287.50 532.92 14.16 16.49 22.41 24.63
Dividend Payout % -0% -0% -0% -0% -0% -0% -0% -0%
Compounded Sales Growth
10 Years: %
5 Years: 32%
3 Years: 21%
TTM: 31%
Compounded Profit Growth
10 Years: %
5 Years: 33%
3 Years: 29%
TTM: 10%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -5%
Return on Equity
10 Years: %
5 Years: 17%
3 Years: 15%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 12 12 12 12 48 57 57 57
Reserves 70 98 133 197 229 774 902 1,034
72 54 46 199 237 245 338 344
68 81 179 167 191 240 271 403
Total Liabilities 223 245 370 575 704 1,316 1,568 1,837
78 73 79 183 183 358 830 842
CWIP -0 -0 7 0 22 341 23 16
Investments -0 -0 -0 -0 -0 -0 -0 41
144 172 283 392 500 617 716 939
Total Assets 223 245 370 575 704 1,316 1,568 1,837

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
19 31 42 59 67 146 64 117
-9 -6 -20 -188 -91 -499 -152 -107
-9 -23 -19 125 27 361 92 -22
Net Cash Flow 1 1 3 -5 3 8 4 -12
Free Cash Flow 11 27 23 -21 -11 -141 -108 55
CFO/OP 68% 79% 101% 83% 76% 113% 47% 59%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 93 85 123 97 104 97 97 98
Inventory Days 50 84 107 76 77 91 119 98
Days Payable 80 92 132 86 105 113 115 110
Cash Conversion Cycle 64 77 99 87 77 75 101 86
Working Capital Days 30 45 39 37 58 77 81 95
ROCE % 26% 28% 31% 24% 19% 15% 15%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Fixed Asset Turnover Ratio (FATR) - Standalone Base
x

Log in to view insights

Please log in to see hidden values.

Login
Installed Capacity - Capsules
Million Units ・Standalone data
Installed Capacity - Tablets
Million Units ・Standalone data
Net Working Capital Days
Days
Actual Production - Capsules
Million Units ・Standalone data
Actual Production - Tablets
Million Units ・Standalone data
CDMO Customers Count
Units
Export Presence (Count of Countries)
Units
Number of CDMO Products Sold
Units
Indian Formulation CDMO Market Share
%
Pharmacy Touchpoints in India
Units

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
50.90% 50.90% 50.90% 50.90% 50.90% 50.90% 50.90% 50.90% 50.90% 50.90%
3.57% 1.94% 1.19% 1.01% 0.74% 0.35% 0.23% 0.08% 0.10% 0.23%
10.31% 20.78% 21.24% 20.61% 19.96% 19.77% 19.67% 20.17% 20.24% 20.14%
35.22% 26.39% 26.67% 27.48% 28.41% 29.00% 29.20% 28.86% 28.76% 28.74%
No. of Shareholders 1,39,11739,39635,11532,25436,69239,99641,01440,24538,69136,965

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls